GMB (trade union)

INNODEM NEUROSCIENCES SIGNS A STRATEGIC COMMERCIAL FRAMEWORK AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA INC.

Retrieved on: 
星期四, 九月 7, 2023
Cognition, EMB Consultancy, Food, Medicine, Multiple sclerosis, Eye, MS, Tablet, Biomarker, HIV disease progression rates, Novartis, Machine learning, Algorithm, Neuroscience, Entrepreneurship, AI, FDA, GMB (trade union), Pharmaceutical industry, Frontiers, Neurology

MONTREAL, Sept. 7, 2023 /PRNewswire/ - Innodem Neurosciences, a leading digital health and AI company, announced today that it has signed a multimillion, multi-year Commercial Framework Agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to support its continued efforts towards its innovative ETNATM technology (Eye Tracking Neurological Assessment).

Key Points: 
  • MONTREAL, Sept. 7, 2023 /PRNewswire/ - Innodem Neurosciences, a leading digital health and AI company, announced today that it has signed a multimillion, multi-year Commercial Framework Agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to support its continued efforts towards its innovative ETNATM technology (Eye Tracking Neurological Assessment).
  • This commercial agreement follows the favorable results of the observational trial involving people living with multiple sclerosis (MS).
  • The peer reviewed performance data, which are the subject of a publication in Frontiers in Neurology, can be accessed here: https://www.frontiersin.org/articles/10.3389/fneur.2023.1243594/abstract .
  • Novartis has recognized Innodem's scalable technology and pending its regulatory clearance, intends to help us bring it to the mainstream with this collaboration," said Marc Reeves, Co-Founder and Chief Business Officer, Innodem Neurosciences.

INNODEM NEUROSCIENCES SIGNS A STRATEGIC COMMERCIAL FRAMEWORK AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA INC.

Retrieved on: 
星期四, 九月 7, 2023
Cognition, EMB Consultancy, Food, Medicine, Multiple sclerosis, Eye, MS, Tablet, Biomarker, HIV disease progression rates, Novartis, Machine learning, Algorithm, Neuroscience, Entrepreneurship, AI, FDA, GMB (trade union), Pharmaceutical industry, Frontiers, Neurology

MONTREAL, Sept. 7, 2023 /PRNewswire/ -- Innodem Neurosciences, a leading digital health and AI company, announced today that it has signed a multimillion, multi-year Commercial Framework Agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to support its continued efforts towards its innovative ETNATM technology (Eye Tracking Neurological Assessment).

Key Points: 
  • MONTREAL, Sept. 7, 2023 /PRNewswire/ -- Innodem Neurosciences, a leading digital health and AI company, announced today that it has signed a multimillion, multi-year Commercial Framework Agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to support its continued efforts towards its innovative ETNATM technology (Eye Tracking Neurological Assessment).
  • This commercial agreement follows the favorable results of the observational trial involving people living with multiple sclerosis (MS).
  • The peer reviewed performance data, which are the subject of a publication in Frontiers in Neurology, can be accessed here: https://www.frontiersin.org/articles/10.3389/fneur.2023.1243594/abstract .
  • Novartis has recognized Innodem's scalable technology and pending its regulatory clearance, intends to help us bring it to the mainstream with this collaboration," said Marc Reeves, Co-Founder and Chief Business Officer, Innodem Neurosciences.

ETNA™ DEVICE FROM THE LEADING DIGITAL HEALTH & AI COMPANY INNODEM NEUROSCIENCES RECEIVES FDA "BREAKTHROUGH" DESIGNATION FOR MULTIPLE SCLEROSIS

Retrieved on: 
星期二, 五月 31, 2022
Google Images, Magnetic resonance imaging, MRI, SPMS, Goto, De novo, Literature, Self-test of intelligence, EMB Consultancy, Sclerosis, Quality of life, Clinical trial, Algorithm, Neurodegeneration, Brain, Alzheimer's disease, EDSS, Multiple sclerosis, DC, Frontotemporal dementia, PPMS, Eye, RRMS, Eye movement, GMB (trade union), IVD, Robotics, MCRA, Elective surgery, McGill University, Partnership, General surgery, Spine, Consultant, Parkinson's disease, Neuroscience, Patient, Neurology, Industry, Urology, Minuteman Library Network, Biomarker, Contract research organization, CRO, Technology, HIV disease progression rates, HIPAA, Intelligence, Diagnosis, Medical device, CEO, Medical imaging

"Eye tracking technology has been around for decades, and the literature demonstrates that eye movements can serve as powerful markers of brain health, particularly in MS.

Key Points: 
  • "Eye tracking technology has been around for decades, and the literature demonstrates that eye movements can serve as powerful markers of brain health, particularly in MS.
  • However, this technology was complex to use, expensive, and the data collected did not allow clinicians to benefit from it for their patients.
  • Up until now, with current standard of care in MS, several years are usually required before clinicians confidently establish the presence of disease progression.
  • www.innodemneurosciences.com
    MCRA is the leading privately held independent medical device and biologics Clinical Research Organization (CRO) and advisory firm.

ETNA™ DEVICE FROM THE LEADING DIGITAL HEALTH & AI COMPANY INNODEM NEUROSCIENCES RECEIVES FDA "BREAKTHROUGH" DESIGNATION FOR MULTIPLE SCLEROSIS

Retrieved on: 
星期二, 五月 31, 2022
CEO, Google Images, Consultant, Parkinson's disease, PPMS, Eye, Neuroscience, RRMS, Partnership, Magnetic resonance imaging, Eye movement, Patient, MRI, GMB (trade union), SPMS, Sclerosis, IVD, Quality of life, Neurology, Clinical trial, Robotics, MCRA, Algorithm, Goto, McGill University, Neurodegeneration, Brain, Elective surgery, Industry, Urology, De novo, Literature, Minuteman Library Network, Biomarker, Contract research organization, Alzheimer's disease, Self-test of intelligence, CRO, EDSS, General surgery, Multiple sclerosis, Technology, HIV disease progression rates, HIPAA, Intelligence, Spine, EMB Consultancy, Diagnosis, DC, Medical device, Frontotemporal dementia, Medical imaging

"Eye tracking technology has been around for decades, and the literature demonstrates that eye movements can serve as powerful markers of brain health, particularly in MS.

Key Points: 
  • "Eye tracking technology has been around for decades, and the literature demonstrates that eye movements can serve as powerful markers of brain health, particularly in MS.
  • However, this technology was complex to use, expensive, and the data collected did not allow clinicians to benefit from it for their patients.
  • Up until now, with current standard of care in MS, several years are usually required before clinicians confidently establish the presence of disease progression.
  • www.innodemneurosciences.com
    MCRA is the leading privately held independent medical device and biologics Clinical Research Organization (CRO) and advisory firm.

Innodem Neurosciences Signs a Strategic Partnership with Novartis Pharmaceuticals Canada Inc.

Retrieved on: 
星期二, 十月 5, 2021
Clinical trial, Neurodegeneration, Partnership, EDSS, Frontotemporal dementia, MRI, Diagnosis, GMB, Novartis, Solution, Parkinson's disease, MSFC, Eye movement, Alzheimer's disease, Multiple sclerosis functional composite, CEO, MS, Magnetic resonance imaging, Biomarker, EMB Consultancy, HIV disease progression rates, Technology, Gold, GMB (trade union), Neuroscience, Multiple sclerosis, Digital, Pharmaceutical industry, Medical imaging

MONTREAL, Oct. 5, 2021 /PRNewswire/ - Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with multiple sclerosis (MS).

Key Points: 
  • MONTREAL, Oct. 5, 2021 /PRNewswire/ - Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with multiple sclerosis (MS).
  • "The financing from Novartis will fund a carefully designed cross-sectional and longitudinal MS study that will last until 2027.
  • "This partnership is the result of an ongoing collaboration that was architected over the past two years.
  • "At Novartis, we are committed to innovation and becoming the leaders in the health tech space.

Innodem Neurosciences Signs a Strategic Partnership with Novartis Pharmaceuticals Canada Inc.

Retrieved on: 
星期二, 十月 5, 2021
Clinical trial, Neurodegeneration, Partnership, EDSS, Frontotemporal dementia, MRI, Diagnosis, GMB, Novartis, Solution, Parkinson's disease, MSFC, Eye movement, Alzheimer's disease, Multiple sclerosis functional composite, CEO, MS, Magnetic resonance imaging, Biomarker, EMB Consultancy, HIV disease progression rates, Technology, Gold, GMB (trade union), Neuroscience, Multiple sclerosis, Digital, Pharmaceutical industry, Medical imaging

MONTREAL, Oct. 5, 2021 /PRNewswire/ -- Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with multiple sclerosis (MS).

Key Points: 
  • MONTREAL, Oct. 5, 2021 /PRNewswire/ -- Innodem Neurosciences announced today that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a breakthrough clinical trial to help people living with multiple sclerosis (MS).
  • "The financing from Novartis will fund a carefully designed cross-sectional and longitudinal MS study that will last until 2027.
  • "This partnership is the result of an ongoing collaboration that was architected over the past two years.
  • "At Novartis, we are committed to innovation and becoming the leaders in the health tech space.